ArticleArchives of disease in childhood2018
Evaluation of newborn sickle cell screening programme in England: 2010-2016.
Article in Archives of disease in childhood, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 1 synthesis or guideline pooled it, 67 citations in OpenAlex.
- Screening for sickle cell disease in newborns: a systematic review.Systematic reviews · 2020Pooled it
- Mortality trends and socioeconomic inequalities in sickle cell disease in Colombia, 2012-2023: a population-based study.Orphanet journal of rare diseases · 2026Article
- Newborn screening results for sickle cell disease from the ASH Consortium on Newborn Screening in Africa (CONSA).Blood advances · 2026Article
- Continuum of care after newborn screening for sickle cell disease: Multinational evidence from a systematic review and meta-analysis.British journal of haematology · 2026Article
- Advances and Gaps in Global Newborn Screening for Sickle Cell Disease.International journal of neonatal screening · 2026Article
- Sickle cell disease screening: Experiences of parents with positive newborns at Korle Bu TeachingHospital.PloS one · 2026Article
- Association between sickle cell anaemia and dental caries among children in Nigeria.BMC oral health · 2025Article
- Emerging Technologies and Advanced Strategies in Hemoglobin Defect Screening.Journal of clinical medicine · 2025Review
- Cost-effectiveness of interventions for screening and management of sickle cell disease during pregnancy: A systematic review.Pregnancy (Hoboken, N.J.) · 2025Review
- Newborn Screening for Sickle Cell Disease: Results from a Pilot Study in the Portuguese Population.International journal of neonatal screening · 2025Article
- Ten years of a neonatal screening program for hemoglobinopathies in Friuli-Venezia Giulia: first regional experience in Italy.Blood transfusion = Trasfusione del sangue · 2024Article
- Newborn Screening for Sickle Cell Disease in Catalonia between 2015 and 2022-Epidemiology and Impact on Clinical Events.International journal of neonatal screening · 2024Article
- Sickle Cell Disease.Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie · 2024Review
- The value-based price of transformative gene therapy for sickle cell disease: a modeling analysis.Scientific reports · 2024Article
- Systematic Literature Review Shows Gaps in Data on Global Prevalence and Birth Prevalence of Sickle Cell Disease and Sickle Cell Trait: Call for Action to Scale Up and Harmonize Data Collection.Journal of clinical medicine · 2023Review
- Defining global strategies to improve outcomes in sickle cell disease: a Lancet Haematology Commission.The Lancet. Haematology · 2023Review
- Sickle Cell Disease Newborn Screening-An Audit of a Twin Island State Pilot Program.International journal of neonatal screening · 2023Article
- Building research capacity for sickle cell disease in Africa: Lessons and challenges from establishing a birth cohort in Tanzania.Frontiers in pediatrics · 2022Article
- Neonatal Screening for Sickle Cell Disease in Congo.Anemia · 2022Article
- Sickle Cell Disease in Children and Adolescents: A Review of the Historical, Clinical, and Public Health Perspective of Sub-Saharan Africa and Beyond.International journal of pediatrics · 2022Review
Corrections and comments
- Commented on by
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
Abstract
objectiveTo evaluate England's NHS newborn sickle cell screening programme performance in children up to the age of 5 years.
designCohort of resident infants with sickle cell disease (SCD) born between 1 September 2010 and 31 August 2015 and followed until August 2016.
participants1317 infants with SCD were notified to the study from all centres in England and 1313 (99%) were followed up.
interventionsEarly enrolment in clinical follow-up, parental education and routine penicillin prophylaxis.
main outcome measuresAge seen by a specialist clinician, age at prescription of penicillin prophylaxis and mortality.
resultsAll but two resident cases of SCD were identified through screening; one baby was enrolled in care after prenatal diagnosis; one baby whose parents refused newborn screening presented symptomatically. There were 1054/1313 (80.3%, 95% CI 78% to 82.4%) SCD cases seen by a specialist by 3 months of age and 1273/1313 (97%, 95% CI 95.9% to 97.8%) by 6 months. The percentage seen by 3 months increased from 77% in 2010 to 85.4% in 2015. 1038/1292 (80.3%, 95% CI 78.1% to 82.5%) were prescribed penicillin by 3 months of age and 1257/1292 (97.3%, 95% CI 96.3% to 98.1%) by 6 months. There were three SCD deaths <5 years caused by invasive pneumococcal disease (IPD) sensitive to penicillin.
conclusionThe SCD screening programme is effective at detecting affected infants. Enrolment into specialist care is timely but below the programme standards. Mortality is reducing but adherence to antibiotic prophylaxis remains important for IPD serotypes not in the current vaccine schedule.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.